# Pierre Combe

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pierre-combe/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,420 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 18 |
| i10-index | 26 |
| Last Known Institution | Hôpital Européen |
| OpenAlex ID | https://openalex.org/A5058312403 |
| ORCID iD | 0000-0002-7321-7345 |
| Works | 101 |

## Researcher papers

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors](https://scholariq.org/papers/vegf-a-modulates-expression-of-inhibitory-checkpoints-on-cd8-t-cells-in-tumors/)
- [Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma](https://scholariq.org/papers/tim-3-expression-on-tumor-infiltrating-pd-1-cd8-t-cells-correlates-with-poor/)
- [CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial](https://scholariq.org/papers/ca-125-elimination-rate-constant-k-kelim-is-a-marker-of-chemosensitivity-in/)
- [Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial](https://scholariq.org/papers/atezolizumab-combined-with-bevacizumab-and-platinum-based-therapy-for-platinum/)
- [Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study](https://scholariq.org/papers/base-position-error-rate-analysis-of-next-generation-sequencing-applied-to/)
- [Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA](https://scholariq.org/papers/analysis-of-base-position-error-rate-of-next-generation-sequencing-to-detect/)
- [Cryopreserved arterial allografts for in situ reconstruction of abdominal aortic native or secondary graft infection](https://scholariq.org/papers/cryopreserved-arterial-allografts-for-in-situ-reconstruction-of-abdominal-aortic/)
- [Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group](https://scholariq.org/papers/cemiplimab-for-locally-advanced-and-metastatic-cutaneous-squamous-cell/)
- [Recurrent ovarian cancer](https://scholariq.org/papers/recurrent-ovarian-cancer/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Researcher university

- [Hôpital Européen](https://scholariq.org/institutions/hopital-europeen/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.